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THC reduces the anticipatory nucleus accumbens
response to reward in subjects with a nicotine
addiction
JM Jansma1,7, HH van Hell1,7, LJMJ Vanderschuren2,3, MG Bossong1,4, G Jager1,5, RS Kahn6 and NF Ramsey1
Recent evidence has implicated the endocannabinoid (eCB) system in nicotine addiction. The eCB system also has an important
role in reward mechanisms, and nicotine addiction has been associated with aberrant reward processing. Motivated by this
evidence, we tested the hypothesis that eCB modulation of reward processing is altered in subjects with a nicotine addiction
(NAD). For this purpose, we compared reward-related activity in NAD with healthy controls (HC) in a pharmacological magnetic
resonance imaging (MRI) study using D9-tetrahydrocannabinol (THC) administration to challenge the eCB system. Eleven HC
and 10 NAD participated in a 3-T functional MRI (fMRI) study with a double-blind, cross-over, placebo-controlled design, using a
Monetary Incentive Delay (MID) paradigmwith three reward levels. Reward activity in the nucleus accumbens (NAcc) and caudate
putamen during anticipation and feedback of reward was compared after THC and placebo. fMRI results indicated a significant
reduction of reward anticipation activity in the NAcc in NAD after THC administration, which was not present in HC. This is
indicated by a significant group by drug by reward interaction. Our data show that THC significantly reduces the NAcc response
to monetary reward anticipation in NAD. These results suggest that nicotine addiction is associated with altered eCB modulation
of reward processing in the NAcc. This study adds important human data to existing evidence implicating the eCB system in
nicotine addiction.
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Introduction
Recent estimates of the World Health Organization have
shown that there are about 1.25 billion smokers worldwide
and that five million deaths occur each year as a direct result
of tobacco use.1 This makes tobacco use one of the most
important causes of preventable death worldwide.
There is increasing evidence that the endocannabinoid
(eCB) system modulates the addictive properties of nicotine,
the main addictive ingredient of tobacco, as well as several
other drugs (see for review, refs. (2–7)). Animal studies
have shown that blocking the eCB receptor CB1 with the
antagonist rimonabant reduces self-administration of
nicotine4,8 and relapse to nicotine seeking (as well as other
drugs, such as cocaine and ethanol).9 Nicotine withdrawal has
been shown to be accompanied by fluctuations in the levels of
the eCB anandamide (AEA) in several brain structures in
rats.10 In humans, clinical trials have indicated that rimona-
bant can facilitate smoking cessation.2,11 The eCB system
has also been widely implicated in the reward properties
of non-drugs,12,13 which has recently been supported by
human neuroimaging studies.14–17 Preclinical studies have,
for instance, shown that CB1 receptor agonists can increase
food intake,18,19 whereas the CB1 antagonist rimonabant
has been demonstrated to reduce obesity11 and reduce
striatal brain activity during reward processing.17 In addition,
there is evidence of deficient reward processing in nicotine
addiction.20–23
Taken together, these findings suggest the possibility that
nicotine addiction may be associated with an altered interac-
tion between the eCB system and reward processing.13 This
paper presents the results of the first human neuroimaging
study that tested the hypothesis that nicotine addiction is
associated with abnormal involvement of the eCB system in
reward processing. The study builds upon a previous study, in
which a similar method was used to examine the involvement
of the eCB system in reward processing in a healthy
population.16 As in the previous study, we performed a
double–blind, cross-over, placebo-controlled pharmacologi-
cal functional magnetic resonance imaging (fMRI) study
probing the brain reward system in which the eCB system
was challenged with D9-tetrahydrocannabinol (THC). Impor-
tantly, in the current study, we compare the effects of THC on
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reward processing in a sample of subjects with a nicotine
addiction (NAD) with a new sample of healthy controls (HC).
Reward processing was assessed using a task based on
the Monetary Incentive Delay (MID) task.24 The MID is an
established reward paradigm that provides the possibility of
separate measures of brain activity related to anticipation of
reward as well as to notification that the reward has been
won. Previous studies using this paradigm have indicated
that anticipation of a reward activates the ventral striatum,
especially in the nucleus accumbens (NAcc).24
Image analyses were focused on the NAcc and caudate
putamen (CPU), areas that have been implicated in addic-
tion25–27 as well as reward processing.14,28 Based on our
hypothesis that nicotine addiction is associated with abnormal
involvement of the eCB system in reward processing, we
expect that THC administration has a stronger effect on the
response of the brain to rewarding stimuli in NAD than in HC.
We postulate that THC should enhance the brain response to
natural rewards in HC, which is in line with previous
publications.13,17 We further expect the enhanced sensitivity
to THC in NAD to lead to a maximized level of activity in the
reward system, resulting in a significantly diminished addi-
tional response to natural rewards.
Methods and materials
This study is part of the Pharmacological Imaging of the
Cannabinoid System (PhICS) study. Methods of the entire
study are reported in detail in a methodological paper.29 The
study is registered in both the EudraCT database (2007-
004247-30) and the Dutch Trial Register (NTR1787).
Although there are previous related publications from the
same project, none of the data presented in this manuscript
have been used in other publications.
Subjects. Fifteen subjects with a nicotine addiction and 17
healthy male subjects participated in a randomized placebo-
controlled cross-over pharmacological MRI study with THC
administration.29 All volunteers gave written informed con-
sent before entry into the study and were paid 250 euro for
participation. The study was approved by the Ethical
Committee of the University Medical Center Utrecht in
accordance with the Declaration of Helsinki 2008.
All subjects were required by the Ethical Committee to be
occasional cannabis users (at least four times a year, at most
once a week) who never had negative experiences after
cannabis use (for instance, a bad trip or cannabis-induced
psychosis), in order to minimize the risk for adverse events.
Subjects were excluded if they or their first-degree relatives
were diagnosed with a psychiatric disorder, as assessed
using the Mini International Neuropsychiatric Interview for
DSM-IV clinical disorders.30 Subjects included in the HC
group did not score on the nicotine addiction questionnaire
FTND (Fagerstrom Test for Nicotine Dependence)31 and
smoked o0.5 cigarettes per day. Subjects included in the
nicotine addiction group had aminimal score of 3 on the FTND
and smoked at least 10 cigarettes per day.Other inclusion and
exclusion criteria are described in detail elsewhere.29
TwoHCwere excluded due to feelings of anxiety during one
of the scanning sessions, two HC due to movement artefacts
and one due to lack of elevated plasma levels of THC. Two
NAD were excluded due to movement artefacts, one due to
feelings of anxiety during one of the scanning sessions and
one due to high blood pressure during the first test day. Two
subjects were excluded as they did not fulfill either the
inclusion criteria for HC or for NAD with regard to nicotine
addiction as applied to the experimental groups for this study.
Results are therefore reported on 11 HC (mean age 21.2
years) and 10 NAD (mean age 25.6 years). Subject
characteristics are presented in detail in Table 1. Subject
demographic characteristics did not show significant group
differences, except as by design for nicotine use last year
(t¼ 11.1, Po0.001) as well as the score on the FTND
(t¼ 13.5; Pp0.001).
Procedure. At a training session, subjects practiced the
procedure of drug administration and participants were
familiarized with the scanning procedure in a ‘mock scanner’
(a non-working replica of a real scanner) to reduce stress
effects on the following test days. The actual study consisted
of 2 test days, separated by at least 2 weeks to allow for
complete clearance of drugs. A standard breakfast or lunch
was provided at the beginning of each test day, to ensure
equal states of metabolism on both of the test days. Subjects
were instructed not to use cannabis for at least 2 weeks
before the first test day. Compliance was tested by means of
Table 1 Results and statistical test results for demographic characteristics
Category HC NAD Effect of group
Mean (±s.e.m.) Range Mean (± s.e.m.) Range t(19) P
Age (years) 21.2±0.8 18–26 25.6±2.1 20–40 1.96 0.07
IQ 105.0±1.5 98–113 107.0±1.6 98–114 0.91 0.37
Cigarettes/day 0.06±0.04 0.0–0.4 17.2±1.5 10–29 11.09 o0.001
FTND 0.0±0.0 0–0 4.3±0.3 3–6 13.50 o0.001
Alcohol units/week 13.2±2.4 3–30 14.4±2.9 2–30 0.33 0.75
Cannabis use last year (no. of occasions) 22.6±3.6 4–52 23.5±5.8 5–52 0.13 0.90
Illicit drug lifetime (no. of occasions) 0.73±0.5 0–6 2.4±1.3 0–13 1.21 0.24
Peak plasma THC level (ngml 1) 82.8±8.2 30–133 81.8±12.3 27–178 0.08 0.94
Abbreviations: FTND, Fagerstrom Test for Nicotine Dependence; HC, healthy controls; NAD, subjects with a nicotine addiction; IQ, Intelligent Quotient;
THC, D9-tetrahydrocannabinol.
Bold typeface and gray background: Po0.05; bold typeface: Po0.1.
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a urine sample at the beginning of each test day. Venous
blood samples were collected to determine plasma concen-
trations of THC and its two most important metabolites,
11-OH-THC and 11-nor-9-carboxy-THC. Blood samples
were processed according to methods published else-
where.29 Subjective effects were measured using a Visual
Analog Scale (VAS) before and after each task, on a scale
from  100 to 100.32,33
Drug administration. THC or placebo was administered
at four time points by inhalation (‘breathing’) using a
Volcano vaporizer29,34 (Storz and Bickel GmbH, Tuttlingen,
Germany). Five minutes before administration, THC was
vaporized at a temperature of 225 1C into an opaque
polythene bag equipped with a mouthpiece, preventing the
loss of THC in between inhalations. Subjects inhaled the
volume of this bag in 2–3min, holding their breath for 10 s
after each inhalation. They were not allowed to speak during
the inhalation process, which was practiced at screening
using placebo. Vehicle (ethanol only) was used as a placebo.
The first dose consisted of 6mg THC or placebo. To maintain
equal levels of intoxication effects throughout the experi-
ment, upload dosages of 1mg were used, 30min apart, in
between scan sessions of different paradigms.
Task. To activate reward circuitry, an adapted version of the
‘MID’ task as developed by Knutson et al.24 was used. In this
task, subjects are required to press a button as fast as
possible on seeing a target stimulus. Depending on the cue
that precedes the target stimulus, subjects can win or lose a
certain amount of money. After each trial in each condition,
except neutral, subjects are given visual feedback, about the
amount won or lost in that trial, as well as the total amount
won (see Figure 1). Brain activity of both anticipation and
feedback of reward and loss can be assessed with this task.
Our MID task had four conditions: neutral, reward (10 cents
(‘small’) or 5 euro (‘large’)) or a loss (5 euro). There were 16
trials for the neutral and reward conditions, and 12 for the loss
condition. The function of the loss trials was to prevent
adaptation to rewards, and they were notmeant to be included
in the analysis. The reward earned by subjects was
dependent on actual task performance.
The reward cue was presented for 0.5 s, while the feedback
was presented for 1.0s. A correct response (‘HIT’) was defined
as a responsebefore the target disappeared. All other responses
are considered incorrect (‘MISS’). Target presentation time was
individually adapted in order to ensure close to 50% correct
responses for each subject, so that all subjects received
comparable total rewards in both of the sessions. This was
achieved by presenting half of the trials 200ms longer and half of
the trails 150ms shorter than the subject’s shortest reaction time
(RT), based on 10 practice trials. The intervals between cue and
target (the anticipation phase or ‘ANT’), between target and
feedback, aswell as the inter-trial interval were varied to allow for
event-related fMRI analysis (see Figure 1).
Scanning parameters. Image acquisition was performed
on a Philips Achieva 3.0 Tesla MR scanner with a Quasar
dual gradient set (Philips Medical Systems, Best, the
Netherlands). Functional imaging was performed in a single
run of 1182 volumes (11min and 51 s) using a SENSE-
PRESTO scan protocol35 (scan parameters: TR (repetition
time) 22.5ms; TE (time to echo) 33.2ms; flip angle¼ 101;
FOV (field of view) 224 256 160; matrix 56 64 40;
voxel size 4.0mm isotropic; scan time 0.6075 s; 40 slices;
sagittal orientation). Before the functional imaging run, a
high-resolution T1-weighted whole-brain anatomical scan
was performed (scan parameters: TR 9.4msec; TE
4.7msec; flip angle¼ 81; FOV 220.8 240 159.6; matrix
368 400 113; voxel size 0.6mm 0.6mm 0.6mm, 266
slices; sagittal orientation).
Analysis. All statistical tests were performed with the
statistical package IBM SPSS Statistics 20 (IBM, New York,
NY, USA).
Demographic, subjective and physiological measures.
Demographic data was tested for group differences with
Figure 1 Task paradigm: Each trial started with a fixation cross, followed by a cue signaling a neutral, potential reward (large or small) or potential loss trial. After the cue, a
target was presented to which subjects had to respond as fast as possible by pressing a button. Reward and loss trials ended with feedback. The time between cue and target
(anticipation phase or ‘ANT’) was varied between trials (4.3–10.3 s; mean 6.6 s), as well as the inter-trial interval (0–30 s; mean 4.2 s).
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paired sample t-tests. VAS scores were corrected for
baseline values and averaged over pre- and post-scan
measurement. VAS scores as well as physiological
measures were tested for effects of drug in HC and group
by drug effects using analysis of variance (ANOVA).
Task performance. Reward task performance was mea-
sured using RTs. A repeated-measures general linear model
(GLM) with drug (placebo, THC) and reward (neutral, small
and large) as within-subject and group as between-subject
factor was performed to tests for effects of THC, reward and
nicotine addiction. In addition, several univariate follow-up
tests were performed.
fMRI. fMRI data were pre-processed and analyzed
using SPM5 (Wellcome Trust Center for Neuroimaging,
London, UK). Pre-processing of data consisted of realign-
ment of functional images and co-registration, spatial
normalization into standard MNI (Montreal Neurological
Institute) space, and spatially smoothing with a Gaussian
filter (full-width half-maximum¼ 8mm). Hypotheses were
tested in a region of interest (ROI) analysis in CPU and
NAcc. NAcc was defined by a 5-mm sphere around
MNI coordinates  12, 14,  8 (left) and 12, 14,  8 (right).
CPU was defined using the AAL (anatomical automatic
labeling) atlas.36
A GLM regression analysis was performed in SPM5 using
an event-related analysis with factors time-locked to task
events, convolved with a canonical hemodynamic response
function. The design included a total of 13 regressors. Four
regressors modeled anticipation activity for each of the four
conditions, using the variable anticipation phase as the
expected duration of each event. Eight regressors modeled
the feedback activity, one for HITS and one for MISSES for
each of the four conditions. Finally, one regressor modeled
response activity for all the four conditions.
To test for effects of THC on reward anticipation,
we averaged beta values over all voxels included in each
ROI, for each condition and each session.
We performed a repeated-measures GLM with ROI
(two levels: left and right), drug (two levels: THC and placebo)
and reward condition (three levels: neutral, small and large) as
within-subject factors and group (HC and NAD) as between-
subject variable. To test for effects of lateralization, we also
performed a four-way interaction test with factors: hemisphere
(two levels: left and right), drug (two levels: THC and placebo)
and reward condition (three levels: neutral, small and large) as
within-subject factors and group (HC and NAD) as between-
subject variable. As follow-up analyses to interpret significant
interaction effects, we tested for effects of reward by group in
the anticipation phase for placebo and THC session sepa-
rately, as well as for the main effects of reward in both the
groups. Finally, we performed tests for main effect of drugs in
HC and NAD, unrelated to reward as well as for drug by group
differences in these main effects. All follow-up tests were also
performed using GLM (repeated measures).
For the feedback phase, the same set of tests was
performed, but now using the contrast between hits
and misses for the two conditions that provided feedback
(‘small’ and ‘large’).
Results
Subjective and physiological results. Detailed results are
presented in Table 1 (peak plasma level) and Table 2.
Subjects showed a peak plasma level of 82.8 for HC and
81.8 for NAD (no significant group difference). VAS scores
indicated a significantly increased score for ‘feeling high’, and
‘external perception’, as well as a significantly reduced score
for ‘alertness’ and ‘contentedness’ in HC and NAD. In
addition, HC showed a significantly increased score for
‘calmness’. In these categories, only ‘calmness’ showed a
Table 2 VAS scores
Category Placebo (mean±s.e.m.) THC (mean±s.e.m.)
HC NAD HC NAD
Feeling high 0.7±1.0 0.0±0.0 29.5±9.2 22.0±6.1
Internal perception 0.2±0.2 0.3±0.3 3.0±2.5 1.1±0.5
External perception 0.6±0.6 0.3±0.2 7.3±2.0 4.7±1.8
Alertness  4.8±2.0 6.2±2.3  15.9±4.0 21.6±3.2
Contentedness  2.9±2.3 3.1±1.6  10.6±2.7 10.0±2.1
Calmness 2.2±3.5 3.6±3.6  13.8±4.7 0.4±3.8
HC (effect of drug) NAD (effect of drug) Drug by group
t(10) p t(9) P F(1,19) p
Feeling high 3.00 0.01 3.66 0.005 0.32 0.58
Internal perception 1.10 0.29 1.35 0.21 0.52 0.48
External perception 2.84 0.01 2.53 0.03 0.58 0.46
Alertness 2.74 0.02 6.48 o0.001 0.83 0.37
Contentedness 2.85 0.02 3.11 0.01 0.06 0.81
Calmness 3.75 0.004 0.80 0.44 4.81 0.04
Abbreviations: HC, healthy controls; NAD, subjects with a nicotine addiction; THC, D9-tetrahydrocannabinol; VAS, Visual Analog Scale.
Results and statistical test results for subjective measurements, as measured with the VAS, averaged over the pre- and post-scan measurement (scale minimum:
 100, maximum: 100, bold typeface and gray background: Po0.05; bold typeface: Po0.1).
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group by drug interaction effect, indicating that while
THC significantly reduced calmness in HC, there was no
effect in NAD.
Task performance. Thresholds for target time, based on
the fastest RT in a task practice session were 272ms (±6
s.e.m.) for HC in the placebo session, 270ms (±6) for HC in
the THC session, 284ms (±4) for NAD in the placebo
session and 302ms (±16) for NAD in the THC session
(main drug effect: F(1,19)¼ 0.64; P¼ 0.43; drug by group:
F(1,19)¼ 0.98; P¼ 0.34).
Reaction times are presented in Figure 2. Tests related
to reward size indicated that in HC RT was reduced with
increasing reward after placebo (F(2,9)¼ 7.95; P¼ 0.01) as
well as after THC (F(2,9)¼ 6.23; P¼ 0.02). Also, RT was
reduced with increasing reward in NAD after placebo
(F(2,8)¼ 11.95; P¼ 0.004), but there was only a trend after
THC (F(2,8)¼ 3.35;P¼ 0.09). Both in HC andNAD, there was
no difference in RT as a result of THC (HC: F(2,9)¼ 0.22;
P¼ 0.80; NAD: F(2,8)¼ 1.14; P¼ 0.37). Also, as a result,
THC did not have a different reward-related effect on
performance in HC and NAD (drug by reward by group:
F(2,18)¼ 0.17; P¼ 0.84).
Other, non-reward-related effects of THC indicated a
significantly increased RT in HC (F(1,10)¼ 5.61; P¼ 0.04),
while there was a trend in NAD (F(1,9)¼ 3.47; P¼ 0.09).
Also, this drug effect was not different between the groups
(F(1,19)¼ 0.56; P¼ 0.46).
fMRI: nucleus accumbens:. A graphical presentation of the
results is shown in Figures 3a–d, while statistical tests are
Figure 2 Reaction times (ms) for the conditions with no reward (‘neutral’), a
0.10 euro (‘small’) or a 5 euro reward (‘large’); (blue lines, squares: healthy controls
(HC); red lines, triangles: subjects with a nicotine addiction (NAD); dark: placebo;
light: D9-tetrahydrocannabinol (THC)).
Figure 3 Above: reward anticipation activity in the (a) left and (b) right nucleus accumbens (NAcc) for the conditions with no reward (‘neutral’), a 0.10 euro (‘small’) or a 5
euro reward (‘large’); (blue: healthy controls (HC); red: subjects with a nicotine addiction (NAD); dark: placebo, light: D9-tetrahydrocannabinol (THC)). HC showed a significant
increase in response with increasing reward. Over hemispheres, we found a significant reduction in NAcc activity in NAD after THC administration. Below: reward
feedback activity in the (c) left and (d) right NAcc for the feedback conditions with a reward (‘small’ or large); (blue: HC; red: subjects with a nicotine addiction; dark: placebo;
light: THC). au, arbitrary units.
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shown in Table 3. An illustration of the activity is presented in
Figure 5.
Anticipation phase. First, we discuss reward-related effects
that are associated with our main hypothesis. For the
NAcc, we found that reward increased brain activity in
NAcc (F(2,9)¼ 4.91; P¼ 0.04), while in NAD there was no
significant increase of brain activity with increasing reward
(F(2,8)¼ 1.36; P¼ 0.31). After placebo, we found no difference
in reward-related activity in NAcc between HC and NAD
(F(2,18)¼ 0.35; P¼ 0.71), while after THC we found a
significantly lower reward response in NAcc in NAD compared
with HC (F(2,18)¼ 7.64; Pp0.001). This different effect of
THC in HC and NAD proved to be significant as indicated by
the main hypothesis test for drug by reward by group
interaction (F(2,18)¼ 3.73; P¼ 0.04), indicating that THC
specifically reduced reward anticipation response in NAcc in
NAD. The effects were not lateralized as indicated by a non-
significant ROI by drug by reward by group interaction
(F(2,18)¼ 0.11; P¼ 0.90). There were no significant non-
reward-related drug effects in the anticipation phase in NAcc.
Feedback phase. In HC, we found a near significant
increase in NAcc response with reward feedback
(F(1,10)¼ 4.38; P¼ 0.06). In NAD, we did not find an effect
of reward feedback (F(1,9)¼ 0.05; P¼ 0.83). However, both
after placebo and after THC, there was no difference in
reward feedback activity between HC and NAD (placebo:
F(1,19)¼ 0.85; P¼ 0.37; THC: F(1,19)¼ 1.01; P¼ 0.33). As
a result, there was also no difference between the groups in
effect of THC on feedback activity in NAcc, as indicated by
the non-significant drug by reward by group interaction
(F(1,19)¼ 0.01; P¼ 0.99). Also, there was no effect of
hemisphere for this interaction (F(1,19)¼ 0.13; P¼ 0.88).
In addition, there were no significant non-reward-related
drug effects in the feedback phase in NAcc.
fMRI: caudate putamen. A graphical presentation of the
results is shown in Figures 4a–d, while statistical tests are
shown in Table 3. An illustration of the activity is presented in
Figure 5.
Anticipation phase. HC showed an increase in CPU brain
activity with increasing reward (F(2,9)¼ 11.6; Po0.001).
In NAD, we did not find a significant increase in CPU activity
with reward (F(2,8)¼ 1.03; P¼ 0.40). In the placebo session,
there was no difference in effect of reward on brain activity
between HC and NAD (F(2,18)¼ 1.89; P¼ 0.18). In the THC
session, there was a significantly smaller effect of reward
in NAD than in HC (F(2,18)¼ 4.36; P¼ 0.03). There was,
however, no significant difference between the groups in effect
of THC on feedback activity in NAcc, as indicated by the non-
significant drug by reward by group interaction (F(2.18)¼ 2.50;
P¼ 0.11). There was also no difference between hemispheres,
as indicated by a non-significant hemisphere effect (hemi-
sphere by drug by reward by group: F(2,18)¼ 1.41; P¼ 0.27).
Table 3 Statistical tests for fMRI measurements
Nucleus accumbens Anticipation phase Feedback phase
F P (df) F P (df)
Hypothesis tests
Drug by reward by group 3.73 0.04 (2,18) 0.01 0.99 (1,19)
Hemisphere by drug by reward by group 0.11 0.90 (2,18) 0.13 0.88 (1,19)
Follow-up tests
Reward by group (placebo) 0.35 0.71 (2,18) 0.85 0.37 (1,19)
Reward by group (THC) 7.64 o0.001 (2,18) 1.02 0.33 (1,19)
HC (main effect of reward) 4.91 0.04 (2,9) 4.38 0.06 (1,10)
NAD (main effect of reward) 1.36 0.31 (2,8) 0.05 0.83 (1,9)
Non-reward tests
HC (main effect of drug) 1.83 0.21 (1,10) 0.26 0.62 (1,10)
NAD (main effect drug) 2.15 0.18 (1,9) 4.05 0.08 (1,9)
Drug by group 3.99 0.06 (1,19) 1.91 0.18 (1,19)
Caudate putamen F p (df) F p (df)
Hypothesis tests
Drug by reward by group 2.50 0.11 (2,18) 0.07 0.80 (1,19)
Hemisphere by drug by reward by group 1.41 0.27 (2,18) 0.34 0.57 (1,19)
Follow-up tests
Reward by group (placebo) 1.89 0.18 (2,18) 1.81 0.19 (1,19)
Reward by group (THC) 4.36 0.03 (2,18) 1.16 0.30 (1,19)
HC(main effect of reward) 11.56 o0.001 (2,9) 6.76 0.03 (1,10)
NAD (main effect of reward) 1.03 0.40 (2,8) 0.01 1.00 (1,9)
Non-reward tests
HC (main effect of drug) 0.30 0.60 (1,10) 0.94 0.36 (1,10)
NAD (main effect of drug) 4.74 0.06 (1,9) 6.37 0.03 (1,9)
Drug by group 0.85 0.37 (1,19) 0.45 0.51 (1,19)
Abbreviations: df, degrees of freedom; fMRI, functional magnetic resonance imaging; HC, healthy controls; NAD, subjects with a nicotine addiction; THC, D9-
tetrahydrocannabinol.
Statistical tests for fMRI measurements in nucleus accumbens and caudate putamen (general linear model, repeated measures; bold typeface and gray background:
Po0.05 bold typeface: Po0.1).
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Other non-reward-related effects in CPU indicated that NAD
showed a general reduction in activity in anticipation phase
after THC that was near significant (F(1,9)¼ 4.74; P¼ 0.06),
while HC did not (F¼ 0.30; P¼ 0.60). There was, however, no
significant difference between the groups (F(1,19)¼ 0.85;
P¼ 0.37).
Feedback phase. In the feedback phase, HC showed
a significant increase in CPU activity with increasing
reward (F(1,10)¼ 6.76; P¼ 0.03). This increase was not
present in NAD (F(1,9)¼ 0.01; P¼ 0.99). However,
both in the placebo session as well as in the THC session,
we did not find a group difference in brain activity in CPU
related to feedback (placebo: F(1,19)¼ 1.81; P¼ 0.19;
THC: F¼ 1.16; P¼ 0.30). Also, there was no difference in
the effect of THC on reward feedback-related activity
between HC and NAD (F(1,19)¼ 0.07; 0.80). Additionally,
there were no significant reward-independent feedback
effects in CPU.
Aversive trials. Although the aversive trials included in our
design were only meant to increase response on rewarding
trials and not meant to be included in the analysis, for
completeness we report that a separate analysis of these
trials showed that for placebo the amplitude for aversive
trials was in between the small and larger reward. As in
the reward trials, NAD also showed a significantly
reduced NAcc response for reward anticipation after THC
in the aversive trials. However, group effects were not
significant.
Discussion
The present study tested the hypothesis that nicotine
addiction is associated with abnormal involvement of the
eCB system in reward processing. This hypothesis was tested
using an eCB challenge with THC in a pharmacological fMRI
Figure 4 Above: reward anticipation activity in the (a) left and (b) right caudate putamen (CPU) for the conditions (neutral’, ‘small’ or ‘large’); (blue: healthy controls (HC);
red: subjects with a nicotine addiction (NAD); dark: placebo; light: D9-tetrahydrocannabinol (THC)). Over hemispheres, HC showed a significant increase in activity with
increasing reward. NAD did not show a significant increase, but group differences were not significant. Below: reward feedback activity in the (c) left and (d) right CPU for the
feedback conditions with a reward (‘small’ or ‘large’); (blue: HC; red: NAD; dark: placebo; light: THC). HC showed a significant increase with increasing reward, while NAD did
not. However, group differences were not significant. (au, arbitrary units)
Figure 5 Illustration of brain activity during anticipation (coronal slices at MNI
(Montreal Neurological Institute) y-coordinate 12, contrast: large versus rest,
|t|43.0, L, left hemisphere, R, right hemisphere). Above: healthy controls (HC),
below: subjects with a nicotine addiction (NAD). Left: placebo session, right:
D9-tetrahydrocannabinol (THC) session.
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experiment. Subjective measures indicated that THC had a
measurable effect on the mental state of our subjects. Both
HC and NAD reported increased levels of ‘feeling high’,
reduced alertness, reduced contentedness and external
perception. Calmness was only significantly reduced in HC,
but the level of the reduction was small.
We measured the functional response in NAcc and
CPU to anticipation and feedback of monetary reward after
placebo and THC in both of the groups. The key finding
of the study was that HC and NAD showed opposite
effects in NAcc response on monetary reward anticipation
after THC administration. Although THC administration in
NAD caused a significantly reduced NAcc response, in HC
there was a slightly increased NAcc response. The effects
appear to be similar but weaker in the CPU. First, there
was also no significant difference in reward anticipation
response in the placebo session. Second, we also found a
significant lower anticipation response in NAD than in HC
in the THC session. However, in CPU, unlike in NAcc,
the difference between the placebo and the THC session was
not significant.
These results support the notion that altered eCB
dynamics in the context of reward processing have a role in
nicotine addiction, adding human findings to the evidence that
the eCB system is involved in nicotine addiction.37 Our
expectation that THCwould have an opposite effect on reward
processing in HC and NAD appeared to be supported by the
reward anticipation results in NAcc. As can be seen in Figures
3a and b, THC reduces brain activity in NAcc in NAD, whereas
this effect appears to be opposite in HC.
Our results suggest that in nicotine addiction the eCB
system may have a stronger influence on the reward system
than in HC. In HC, the slight increase in reward anticipation
activity (although by itself not significant) is in line with
previous reports that indicate that administration of eCB
antagonist Rimonabant can reduce rewarding effects.17 By
contrast, the absence of an anticipatory NAcc response to
monetary reward after THC in NAD suggests the possibility of
a ceiling effect on activity in NAcc, which is not present in HC.
If activity is strongly elevated by THC in NAD during baseline,
this may leave less room for further elevation of activity by the
monetary stimuli. This difference between HC andNAD could,
therefore, be due to a maximized level of dopamine receptor
occupation in NAD after THC due to reduced availability of
dopamine D2 receptors.38 In HC, THC also increases
dopamine receptor occupancy, but as dopamine receptor
availability is not compromised, there is room for a further
increase in response to a monetary reward. In addition, it is
also possible that nicotine addiction is associated with altered
sensitivity to THC or non-dopaminergic mechanisms in NAcc
(for example, Berridge and Kringelbach28).
The abnormal NAcc response in NAD to monetary rewards
after THC may be related to prodromal differences in eCB
function, potentially constituting a predisposition to addiction.
Activation of nicotinic receptors on dopaminergic neurons in
the ventral tegmental area by nicotine is hypothesized to
increase release of the eCB AEA.39,40 Functional mutations in
the CB1 cannabinoid receptor and fatty acid amide hydrolyze
genes (FAAH; the main enzyme that breaks down AEA) have
been linked to rewarding effects of nicotine as well as
other drugs such as cocaine, alcohol, marijuana and
heroin.10,37,41,42 Inhibition of FAAH with a selective inhibitor
URB 597 has been shown to enhance nicotine reward in
mice.37 This is hypothesized to be a direct result of increased
levels of AEA. On the other hand, URB 597 has also been
shown to neutralize rewarding effects of nicotine.43–45 The
proposed mechanisms for this effect is that AEA is protected
from rapid degradation by URB597, resulting in increased
activation of CB1 receptors. This reduces activation of
dopaminergic neurons and release of dopamine from their
terminals in the NAcc shell. It has been previously suggested
that the different effects are dose related.46 Although the exact
working mechanisms may still be unknown, a recent review
provides several convincing arguments for a direct link
between the eCB system and addiction, associated with
polymorphisms in the CB1 cannabinoid receptor and FAAH
genes.7 The current study is one of the first to add human
brain imaging results to support this view.
Although the present study sample only included subjects
with a nicotine addiction, the results may be relevant for other
drug addictions as well. It is known that addiction to nicotine
causes comparable reductions in striatal DA D2 receptor
density as addiction to other drugs of abuse.38,47 There is
evidence suggesting an interaction between the eCB system
and alcohol dependence.48 In addition, animal studies have
shown that chronic exposure to nicotine, alcohol and THC (but
not cocaine) increases eCB levels in the limbic forebrain,
including the NAcc.49,50 These results suggest the possibility
of a general involvement of eCB in drug addiction.2 However,
whether our results can be extrapolated to addiction in general
warrants further investigation.
In addition to the main finding, there were several other
notable findings in this study.
Our results in the placebo session in HC support those
previously found with the MID task, as previous studies using
this paradigm have indicated that anticipation of an increasing
reward evokes an increasing response that is most pro-
nounced in NAcc.24,51
Our results also showed feedback-related activity in HC in
CPU that was reward-size dependent. However, in contrast
to previous studies using the MID paradigm, we also found a
near significant reward feedback activity in NAcc.24,52 This
finding is potentially related to the applied ROI-based
analysis, which is more powerful than the more commonly
applied voxel-wise analysis.
In contrast to some previous studies, we did not find a
significant difference between HC and NAD in reward anticipa-
tion activity in NAcc after placebo. What may have influenced
the NAcc results is the fact that all our subjects were occa-
sional cannabis users, as well as that our HC were occasional
smokers. Indeed, in a previous study, we found that NAD as
well as cannabis users both showed a significantly reduced
reward anticipation response in NAcc, compared with
subjects who had never smoked or used cannabis.15 It has
to be noted, however, that previous results in this regard are
inconsistent, as some have reported reduced response to
monetary reward anticipation in nicotine addiction,22,23 while
others did not.21,53 Likewise, reward studies using alcohol-
dependent subjects also provide inconsistent results. Two
studies have reported decreased activation in ventral
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striatum,54,55 and one study showed normal activity during
reward anticipation in the MID task.56
In our study, NAD showed reduced feedback response in
CPU, (and a trend for a similar effect in NAcc) after THC. This
is also in line with the presented hypothesis that THC
maximally activated the reward system in NAD, leaving less
room for an additional response to monetary reward.
Behaviorally, we found that THC increased RT in HC as
well as NAD. However, this effect was not reward dependent.
The general effect of THC on RT is consistent with the
reduced perceived alertness, measured with the VAS. Also,
we did not find any group differences in the effect of THC on
performance despite the difference in brain activity. There can
be several explanations for this. The general slowing effect of
THC, indicated by a significant main effect of drug on
performance, may have introduced too much between-
subject variation. Also, it is possible that reward-specific
effects of THC are present but are too small to become
significant owing to our relatively small sample. TheRT effects
do, however, appear to go in the same direction that can be
expected based on the activity results, as the increase in RT in
the largest reward condition is larger for NAD then for HC, as
can be seen in Figure 2.
Somewhat surprisingly, we did not find an effect of THC on
reward anticipation reactivity in CPU and NAcc in HC. Human
imaging studies on these effects are sparse, and to our
knowledge there is only one other study on this topic, also
from our group.16 In that study, using a comparable experi-
mental design, we also did not find a significant effect of THC
on NAcc activity. It has to be noted, however, that NAcc
showed low activity for all conditions in that study. In addition,
Van Hell et al.16 did report significant striatal response to
reward anticipation that also was not affected by THC. As the
current study replicated this finding, the lack of effect of THC
on reward anticipation in humans (not addicted to nicotine)
appears to be a reliable finding. It has to be taken into account,
however, that due to ethics protocol requirements, in both
studies HC were infrequent nicotine users as well as
infrequent cannabis users, as THC is typically mixed with
tobacco. This in contrast to several other studies where HC
were nicotine-free.15,22,53,57 This also may have reduced the
difference between NAD and HC in the placebo session.
Our results may also have been influenced by the fact that
NAD were nicotine-abstinent for about 3 h when performing
the experimental task. This period was needed to ensure
absence of acute effects of nicotine. The possibility that
subjects were experiencing some withdrawal effects at the
time of testing can, however, not be excluded, as early effects
of withdrawal have been reported within 60min.58 However,
responses to the VAS during scanning did not suggest effects
of withdrawal in NAD.
Although our ROI analyses are not corrected for multiple
comparison, we do not feel that we capitalized on chance, as
we only tested two ROIs. Additionally, although the main
three-way interaction in NAcc changes to near significance
after correction for two ROIs (P¼ 0.06), many of the follow-up
ANOVA effects that drive this interaction do survive correction
for two ROIs. In this study, a cannabinoid agonist was used to
investigate the role of the endogenous cannabinoid system.
Although this is a well-established method of studying
cannabinoid function, a disadvantage is that cannabinoid
agonists like THC can activate cannabinoid receptors
everywhere in the brain, regardless of the endogenous
activity of the system. Future experiments that make use of
a cannabinoid antagonist could have an important role in
confirming the role of the endogenous system in reward
processing in addiction.
We did not test for differences between HC and NAD in
impulsivity, anxiety and depression. Also, there was a trend
that the average age of NADwas higher than HC in the current
study. These variables may have influenced our results.
However, it should be noted that potential group differences
were not reflected in the VAS, except for a small effect in
‘calmness’, but this showed that in HC calmness was more
reduced after THC. Also, target presentation time, which was
based on the shortest RT in a task practice session, was not
significantly different between HC and NAD, indicating that a
potential group difference in impulsivity did not affect task
performance.
As THC was dissolved in 100 vol% alcohol and the solvent
was used as placebo, we cannot exclude that the inhalation of
alcohol might have affected blood alcohol concentration.
However, as only 600ml alcohol was administered, this is very
unlikely. As a comparison, this amount is less than one-tenth
of one alcoholic beverage.
In conclusion, our study showed that in NAD the NAcc
response to reward anticipation is significantly reduced after
THC administration, while the response in HC was the
opposite. These results suggest that nicotine addiction is
associated with altered eCB modulation of reward processing
in the NAcc. This study adds human findings to the existing
evidence that identifies the eCB system as a therapeutic
candidate for nicotine addiction.
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